Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aclaris Therapts (NQ: ACRS ) 1.330 +0.010 (+0.76%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 535,170 Open 1.320 Bid (Size) 1.380 (100) Ask (Size) 1.420 (10) Prev. Close 1.320 Today's Range 1.310 - 1.400 52wk Range 0.5902 - 10.71 Shares Outstanding 71,264,786 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices July 11, 2024 Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. Via MarketBeat Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying July 08, 2024 Via Benzinga Performance YTD +26.67% +26.67% 1 Month +3.10% +3.10% 3 Month +9.02% +9.02% 6 Month +5.56% +5.56% 1 Year -86.50% -86.50% More News Read More $1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying June 14, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session May 24, 2024 Via Benzinga ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Aclaris Therapeutics: Q4 Earnings Insights February 27, 2024 Via Benzinga The Analyst Landscape: 4 Takes On Aclaris Therapeutics January 11, 2024 Via Benzinga Breaking Down Aclaris Therapeutics: 6 Analysts Share Their Views December 18, 2023 Via Benzinga Biotech’s Role in Addressing the Pancreatic Cancer Emergency March 14, 2024 Via FinancialNewsMedia Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying March 06, 2024 Via Benzinga Topics Stocks Exposures US Equities Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades January 22, 2024 Via Benzinga Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session January 22, 2024 Via Benzinga Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket January 22, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session January 16, 2024 Via Benzinga Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today? January 16, 2024 Via Benzinga Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations January 10, 2024 Via Benzinga Aclaris Therapeutics Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) December 18, 2023 Via Benzinga Crude Oil Falls 1%; Amarin Shares Spike Higher January 10, 2024 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 10, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session January 10, 2024 Via Benzinga Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week January 10, 2024 Via Benzinga Topics Stocks Exposures US Equities Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial January 10, 2024 Via Benzinga Dow Surges 100 Points; PriceSmart Earnings Top Views January 10, 2024 Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Wednesday's Pre-Market Session January 10, 2024 Via Benzinga Inflammatory Disease Focused Aclaris Therapeutics Reduces Staff After Failed Psoriatic Arthritis Study December 20, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.